Related Experiment Video
Updated: Jun 26, 2025
A 3D Spheroid Model for Glioblastoma
Published on: April 9, 2020
Targeting Integrin α3 Blocks β1 Maturation, Triggers Endoplasmic Reticulum Stress, and Sensitizes Glioblastoma Cells
Yuki Kuranaga1,2, Bing Yu3, Satoru Osuka1,2
1Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Abstract:
Glioblastoma (GBM) is a devastating brain cancer for which new effective therapies are urgently needed. GBM, after an initial response to current treatment regimens, develops therapeutic resistance, leading to rapid patient demise. Cancer cells exhibit an inherent elevation of endoplasmic reticulum (ER) stress due to uncontrolled growth and an unfavorable microenvironment, including hypoxia and nutrient deprivation. Cancer cells utilize the unfolded protein response (UPR) to maintain ER homeostasis, and failure of this response promotes cell death. In this study, as integrins are upregulated in cancer, we have evaluated the therapeutic potential of individually targeting all αβ1 integrin subunits using RNA interference. We found that GBM cells are uniquely susceptible to silencing of integrin α3. Knockdown of α3-induced proapoptotic markers such as PARP cleavage and caspase 3 and 8 activation. Remarkably, we discovered a non-canonical function for α3 in mediating the maturation of integrin β1. In its absence, generation of full length β1 was reduced, immature β1 accumulated, and the cells underwent elevated ER stress with upregulation of death receptor 5 (DR5) expression. Targeting α3 sensitized TRAIL-resistant GBM cancer cells to TRAIL-mediated apoptosis and led to growth inhibition. Our findings offer key new insights into integrin α3's role in GBM survival via the regulation of ER homeostasis and its value as a therapeutic target.
Insights
Targeting integrin alpha3 in glioblastoma (GBM) triggers cancer cell death by disrupting endoplasmic reticulum homeostasis. This approach enhances sensitivity to TRAIL therapy, offering a promising new avenue for treating this aggressive brain cancer.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Glioblastoma (GBM) is an aggressive brain cancer with limited effective therapies.
- Therapeutic resistance and rapid patient decline are hallmarks of GBM progression.
- Cancer cells endure endoplasmic reticulum (ER) stress, utilizing the unfolded protein response (UPR) for survival.
Purpose of the Study:
- To investigate the therapeutic potential of targeting integrin alpha-beta 1 (αβ1) subunits in glioblastoma.
- To explore the role of integrin alpha3 (α3) in GBM cell survival and ER homeostasis.
Main Methods:
- Utilized RNA interference to individually silence all αβ1 integrin subunits in GBM cells.
- Assessed the impact of integrin α3 knockdown on apoptotic markers and ER stress.
- Investigated the non-canonical function of α3 in integrin beta1 (β1) maturation.
Main Results:
- GBM cells showed unique susceptibility to integrin α3 silencing.
- Knockdown of α3 induced apoptosis, evidenced by PARP cleavage and caspase activation.
- Integrin α3 deficiency impaired β1 maturation, increased ER stress, and upregulated death receptor 5 (DR5).
- Targeting α3 sensitized TRAIL-resistant GBM cells to TRAIL-induced apoptosis and inhibited tumor growth.
Conclusions:
- Integrin α3 plays a critical role in GBM cell survival by regulating ER homeostasis.
- Integrin α3 is a potential therapeutic target for glioblastoma.
- Targeting α3 enhances the efficacy of TRAIL-based therapies in GBM.
